ID: ALA2235005

Max Phase: Preclinical

Molecular Formula: C16H12N4O2S

Molecular Weight: 324.37

Molecule Type: Small molecule

Associated Items:

Representations

Canonical SMILES:  COc1ccc2nc(NC(=O)Nc3ccc(C#N)cc3)sc2c1

Standard InChI:  InChI=1S/C16H12N4O2S/c1-22-12-6-7-13-14(8-12)23-16(19-13)20-15(21)18-11-4-2-10(9-17)3-5-11/h2-8H,1H3,(H2,18,19,20,21)

Standard InChI Key:  YXNFNJDPRQHECY-UHFFFAOYSA-N

Associated Targets(Human)

Ubiquitin-like modifier-activating enzyme 1 57 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Properties

Molecular Weight: 324.37Molecular Weight (Monoisotopic): 324.0681AlogP: 3.82#Rotatable Bonds: 3
Polar Surface Area: 87.04Molecular Species: NEUTRALHBA: 5HBD: 2
#RO5 Violations: 0HBA (Lipinski): 6HBD (Lipinski): 2#RO5 Violations (Lipinski): 0
CX Acidic pKa: 7.29CX Basic pKa: CX LogP: 3.64CX LogD: 3.31
Aromatic Rings: 3Heavy Atoms: 23QED Weighted: 0.77Np Likeness Score: -2.52

References

1. Caputo R, Calabro ML, Micale N, Schimmer AD, Ali M, Zappala M, Grasso S.  (2012)  Synthesis of benzothiazole derivatives and their biological evaluation as anticancer agents,  21  (9): [10.1007/s00044-011-9789-8]

Source